Abstract:Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal, not malignant, hematological disease characterized by intravascular hemolysis, thrombophilia and bone marrow failure. While this latter presentation is due to a T-cell mediated auto-immune disorder resembling acquired aplastic anemia, the first two clinical presentations are largely driven by the complement pathway. Indeed, PNH is characterized by a broad impairment of complement regulation on affected cells, which is due to the lack of the complement regulators CD55 and CD59. The deficiency of these two proteins from PNH blood cells is due to the somatic mutation in the phosphatidylinositol N-acetylglucosaminyltransferase subunit A gene causing the disease, which impairs the surface expression of all proteins linked via the glycosylphosphatidylinositol anchor. The lack of the complement regulators CD55 and CD59 on PNH erythrocytes accounts for the hallmark of PNH, which is the chronic, complement-mediated intravascular hemolysis. This hemolysis results from the impaired regulation of the alternative pathway upstream in the complement cascade, as well as of the downstream terminal pathway. PNH represented the first indication for the development of anti-complement agents, and the therapeutic interception of the complement cascade at the level of C5 led to remarkable changes in the natural history of the disease. Nevertheless, the clinical use of an inhibitor of the terminal pathway highlighted the broader derangement of complement regulation in PNH, shedding light on the pivotal role of the complement alternative pathway. Here we review the current understanding of the role of the alternative pathway in PNH, including the emergence of C3-mediated extravascular hemolysis in PNH patients on anti-C5 therapies. These observations provide the rationale for the development of novel complement inhibitors for the treatment of PNH. Recent preclinical and clinical data on proximal complement inhibitors intercepting the alternative pathway with the aim of improving the treatment of PNH are discussed, together with their clinical implications which are animating a lively debate in the scientific community.

Buried Hydrogen Bond Interactions Contribute to the High Potency of Complement Factor D Inhibitors.

Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway

Reconstitution of the alternative pathway of the complement system enables rapid delineation of the mechanism of action of novel inhibitors

Structural Basis for Properdin Oligomerization and Convertase Stimulation in the Human Complement System.

Properdin Oligomers Adopt Rigid Extended Conformations Supporting Function

Discovery and Structural Modification of 1-Phenyl-3-(1-phenylethyl)urea Derivatives As Inhibitors of Complement

Disease-linked mutations in factor H reveal pivotal role of cofactor activity in self-surface-selective regulation of complement activation

The Solvent at Antigen-Binding Site Regulated C3d-CR2 Interactions Through the C-terminal Tail of C3d at Different Ion Strengths: Insights from Molecular Dynamics Simulation.

Therapeutic targeting of factor D and MASP3 in complement‐mediated diseases: Lessons learned from mouse studies

The human complement factor B-C3b complex: Investigation of the interaction using C3b bound to thiol-Sepharose

The complement model disease paroxysmal nocturnal hemoglobinuria

Conjugation to albumin-binding molecule tags as a strategy to improve both efficacy and pharmacokinetic properties of the complement inhibitor compstatin.

Heparin Regulation of the Complement System

Anti-human Properdin Monoclonal Antibody Dose-Dependently Inhibits Complement-Mediated Lysis of PNH Erythrocytes in Ham's Test and Prevents Extravascular Hemolysis in a Human Properdin Transgenic Mouse Model

Identification Of A Complement Receptor 1 Peptide For Inhibition Of Immune Hemolysis

Complement-Coagulation Cross-talk: Factor H-mediated regulation of the Complement Classical Pathway activation by fibrin clots

Molecular Docking And Molecular Dynamics (Md) Simulation Of Human Anti-Complement Factor H (Cfh) Antibody Ab42 And Cfh Polypeptide

gC1qR/C1qBP/HABP-1: Structural Analysis of the Trimeric Core Region, Interactions With a Novel Panel of Monoclonal Antibodies, and Their Influence on Binding to FXII

The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target

Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes

Peptide Inhibitors of C3 Activation As a Novel Strategy of Complement Inhibition for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.